VIR Live signals | Maximize Profits with Getagraph.com

BUY 99553 min ago

@ $9.72

Issued: 14 Feb 2024 @ 13:10

Return: -16.36%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: 6.58 %

Live Chart Being Loaded With Signals

Commentary (23 Apr 2024 @ 16:00):

Stats
Today's Volume	762 454
Average Volume	1.08M
Market Cap	1.10B
EPS	$0 ( 2024-02-22 )
Next earnings date	( $-0.990 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.770
ATR14	$0.00700 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-03	De Backer Marianne	Sell	72 995	Common Stock
2024-04-01	Hanly Ann M.	Sell	2 711	Common Stock
2024-03-27	Lee Sung	Sell	6 008	Common Stock
2024-02-22	Hanly Ann M.	Buy	32 500	Common Stock
2024-02-22	Hanly Ann M.	Sell	12 296	Common Stock

INSIDER POWER
-10.20
Last 98 transactions
Buy: 8 177 990 \| Sell: 9 772 896

Volume Correlation

Long: -0.36 (neutral)

Short: -0.82 (strong negative)

Signal:(27.184) Be Aware. Possible trading coming up! (swing)

Vir Biotechnology Inc Correlation

10 Most Positive Correlations
MMAC	0.954
BOCH	0.943
NETE	0.913
SHSP	0.859
AMRB	0.843
RAVN	0.843
SILC	0.824
DSPG	0.802

10 Most Negative Correlations
PAIC	-0.934
RMRM	-0.927
SVOK	-0.922
SVAC	-0.888
ISNS	-0.888
APOP	-0.887
FEYE	-0.874
GAINL	-0.872
SPRT	-0.837
TDAC	-0.828

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vir Biotechnology Inc Correlation - Currency/Commodity

-0.27
( neutral )

-0.22
( neutral )

0.00
( neutral )

0.14
( neutral )

0.00
( neutral )

0.63
( weak )

Vir Biotechnology Inc Financials

Annual	2023
Revenue:	$86.18M
Gross Profit:	$63.96M (74.22 %)
EPS:	$-4.59

Q4	2023
Revenue:	$16.79M
Gross Profit:	$11.51M (68.56 %)
EPS:	$-0.860

Q3	2023
Revenue:	$-4.10M
Gross Profit:	$-4.14M (100.93 %)
EPS:	$-1.220

Q2	2023
Revenue:	$-12.72M
Gross Profit:	$-12.74M (100.17 %)
EPS:	$-1.450

Financial Reports:

No articles found.

Vir Biotechnology Inc

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.